EUCTR2018-001508-12-CZ进行中（未招募）1 期
A placebo-controlled, patient and investigator blinded, randomized parallelcohort study to assess pharmacodynamics, pharmacokinetics, safety,tolerability and preliminary clinical efficacy of VAY736 and CFZ533 inpatients with systemic lupus erythematosus (SLE)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent must be obtained before any assessment is performed
- •- Male and female patients 18 to 75 years of age
- •- Fulfill =4 of the 11 American College of Rheumatology 1997 classification criteria for SLE
- •- Patient diagnosed with SLE for at least 6 months prior to screening
- •- Elevated serum titers at screening of ANA (=1:80) of a pattern consistent with an SLE diagnosis, including at a minimum either anti-double stranded DNA (anti-ds DNA) or anti-Ro (SSA) or anti-La (SSB) or anti-nuclear ribonucleoprotein (anti-RNP) or anti-Smith (anti-Sm)
- •- Currently receiving corticosteroids and/or antimalarial and/or thalidomide treatment and/or another DMARD on a stable dose according to protocol requirements
- •- SLEDAI-2K score of =6 at screening
- •- BILAG-2004 score at screening of:
- •?-- at least one A in either the mucocutaneous domain or in the
- •musculoskeletal domain,
- •?-- one B in either the mucocutaneous or musculoskeletal domain
- •AND at least one A or B in a second domain
- •- Weigh at least 40 kg at screening
- •- Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 115
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Cohort 2 (CFZ533/Placebo) only:
- •- Patients who are at significant risk for thromboembolic events based on the following:
- •-- History of either thrombosis or 3 or more spontaneous abortions
- •-- Presence of lupus anticoagulant or significantly prolonged activated partial thromboplastin time (aPTT) consistent with co-existent anti-phospholipid syndrome and without concurrent prophylactic treatment with aspirin or anticoagulants as per local standard of care
- •All Cohorts:
- •- History of receiving prior to screening:
- •-- Within 12 weeks: i.v. corticosteroids, calcineurin inhibitors or other oral DMARD
- •-- Within 24 weeks: cyclophosphamide or biologics such as intravenous Ig, plasmapheresis, anti-TNF-a mAb, CTLA4-Fc Ig (abatacept) or BAFF targeting agents (e.g., belimumab)
- •-- Any B-cell depleting therapies (e.g., anti-CD20 mAb, anti-CD22 mAb, anti-CD52 mAb) or TACI-Ig (atacicept) administered within 52 weeks prior to screening, and a B-cell count <50 cells/µ at the time of
- •- Evidence of past exposure to tuberculosis as assessed by Quantiferon testing at screening
- •- Severe organ dysfunction or life threatening disease;
- •- Presence of severe lupus kidney disease as defined by proteinuria above 6 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.5 mg/dL (221.05 µmol/L), or requiring immune suppressive induction or maintenance treatment exceeding protocol defined limits
- •- Active viral, bacterial or other infections at the time of screening or enrollment
- •- Receipt of live/attenuated vaccine within a 2month period before first dosing
- •- Uncontrolled, co-existing serious disease, e.g., uncontrolled hypertension, heart failure, type I diabetes, thyroid disease within 3 months prior to first dosing, or significant, unresolved illness within 2
- •weeks prior to first dosing
- •- History of hypersensitivity to drugs of similar chemical class
- •- Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Subjects who are HBsAg negative and HBcAb positive are excluded unless negative for HBV DNA. Once past screening and enrolled into study, requirements for monitoring and antiviral treatment are enacted. Subjects with a positive HCV antibody test should have HCV RNA levels measured. Subjects with positive (detectable) HCV RNA should be excluded.
- •- Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)EUCTR2018-001508-12-FRovartis Pharma AG120
已完成
2 期
A study to assess safety and preliminary clinical efficacy of VAY736 and CFZ533 in patients with systemic lupus erythematosussystemic lupus erythematosusJPRN-jRCT2080224123ovartis Pharma K.K.120
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)MedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-001508-12-DEovartis Pharma AG135
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)EUCTR2018-001508-12-ESovartis Farmacéutica, S.A.120
招募中
1 期
A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in participants with knee osteoarthritisMedDRA version: 21.1Level: LLTClassification code: 10023476Term: Knee osteoarthritis Class: 10028395Knee OsteoarthritisCTIS2022-502821-16-00ovartis Pharma AG88